See more : CG-VAK Software and Exports Limited (CGVAK.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Relevium Technologies Inc. (RLLVF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Relevium Technologies Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Wam Alternative Assets Limited (WMA.AX) Income Statement Analysis – Financial Results
- Telefonaktiebolaget LM Ericsson (publ) (ERIXF) Income Statement Analysis – Financial Results
- Kalray S.A. (ALKAL.PA) Income Statement Analysis – Financial Results
- Bite Acquisition Corp. (BITE-UN) Income Statement Analysis – Financial Results
- Inspira Technologies Oxy B.H.N. Ltd. (IINNW) Income Statement Analysis – Financial Results
Relevium Technologies Inc. (RLLVF)
About Relevium Technologies Inc.
Relevium Technologies Inc. engages in the identification, evaluation, acquisition, and operation of brands and businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and cosmeceuticals primarily through its Bioganix brand portfolio online; dietary supplements under the LeefyLyfe brand name; and skin care products under the Push & Pull System brand. It also provides Relevium Senior, a geriatric brand targeting inflammatory conditions, including joints, heart, and brain; and Relevium Kids, a pediatric brand of nutraceuticals and oral nutritional supplements. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. Relevium Technologies Inc. is headquartered in Montreal, Canada.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 913.64K | 2.97M |
| Cost of Revenue | 499.17K | 1.78M |
| Gross Profit | 414.48K | 1.19M |
| Gross Profit Ratio | 45.37% | 40.15% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 1.31M | 2.31M |
| Selling & Marketing | 577.81K | 1.65M |
| SG&A | 1.89M | 3.96M |
| Other Expenses | -1.47M | 0.00 |
| Operating Expenses | 414.48K | 1.19M |
| Cost & Expenses | 913.64K | 2.97M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 750.88K | 566.68K |
| Depreciation & Amortization | 4.66K | 3.42K |
| EBITDA | -4.61M | -4.67M |
| EBITDA Ratio | -504.88% | -157.01% |
| Operating Income | -1.48M | -2.77M |
| Operating Income Ratio | -161.49% | -93.19% |
| Total Other Income/Expenses | -3.89M | -4.16M |
| Income Before Tax | -5.37M | -6.93M |
| Income Before Tax Ratio | -587.57% | -233.06% |
| Income Tax Expense | 0.00 | 0.00 |
| Net Income | -5.37M | -6.93M |
| Net Income Ratio | -587.57% | -233.06% |
| EPS | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 |
Relevium Reports Interim First Quarter Results for the Three-Month Period Ended September 30, 2020
Relevium Reports Fiscal Year Ended June 30, 2020 Results
Relevium Issues Corporate Update on MCTO and Filing of Financial Statements
Relevium Issues Corporate Update on MCTO and Filing of Financial Statements
Relevium Issues Corporate Update on MCTO and Operations
Relevium Provides Regulatory Update on Annual Financials and Management Cease Trade Order
Relevium Provides Update to Management Cease Trade Order
Relevium Announces Delay in Filing Annual Audited Financial Statements
Source: https://incomestatements.info
Category: Stock Reports